Investigational drug · Phase 3
MK-1045
Also called: CN-201
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
8
Any phase or sponsor naming "MK-1045"
First trial start
2022
Nov 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-1045", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular
- Acute Lymphoblastic Leukemia
- Follicular Lymphoma
- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Hematologic Malignancies
- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-Cell Lymphoma
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-1045" as an intervention, largest first.
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07634471 · 960 participants (planned) · Start Jun 22, 2026 · Primary completion Jul 23, 2032
Drug: MK-1045; Rituximab and 7 more · For: Follicular Lymphoma
Sites: Duarte, California; Lexington, Kentucky; Hackensack, New Jersey · 40 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07570173 · 340 participants (planned) · Start May 18, 2026 · Primary completion Oct 18, 2033
Drug: MK-1045; Blinatumomab and 7 more · For: B-cell Acute Lymphoblastic Leukemia
Sites: Toronto, Canada; Copenhagen, Denmark; Aarhus Nord, Denmark · 30 sites in all
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07519772 · 280 participants (planned) · Start May 3, 2026 · Primary completion Jul 1, 2030
Drug: MK-1045 · For: Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Sites: Los Angeles, California; Denver, Colorado; Cleveland, Ohio · 56 sites in all
MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
NCT05579132 · 203 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2028
Drug: MK-1045 · For: Acute Lymphoblastic Leukemia
Sites: Chongqing, China; Guangzhou, China; Shijiazhuang, China · 11 sites in all
MSD R&D (China) Co., Ltd.Merck & Co. (MRK)
NCT06189391 · 100 participants (planned) · Start Mar 16, 2021 · Primary completion Sep 30, 2028
Drug: MK-1045 · For: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sites: Beijing, China; Xiameng, China; Guangzhou, China · 15 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07709000 · 60 participants (planned) · Start Oct 14, 2026 · Primary completion Nov 16, 2033
Drug: MK-1045; Acetaminophen (or similar antipyretic) and 5 more · For: Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies
Sites: Medellín, Colombia; Bogotá, Colombia; Haifa, Israel · 10 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07363590 · 21 participants (planned) · Start Feb 19, 2026 · Primary completion Jul 16, 2029
Drug: MK-1045 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Southport, Australia; Diepenbeek, Belgium; Ghent, Belgium · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lymphoma, Large B-Cell, Diffuse
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- JNJ-90014496Phase 21 trial
Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- Relmacabtagene AutoleucelJWCAR029Phase 21 trial
Shanghai Ming Ju Biotechnology Co., Ltd. · Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.